

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT														
NATURE OF CONVEYANCE:	First Lien Patent Security Agreement														
CONVEYING PARTY DATA															
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:70%;">Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Quintiles Transnational Corp.</td> <td>03/12/2010</td> </tr> <tr> <td>Targeted Molecular Diagnostics, LLC</td> <td>03/12/2010</td> </tr> </tbody> </table>		Name	Execution Date	Quintiles Transnational Corp.	03/12/2010	Targeted Molecular Diagnostics, LLC	03/12/2010								
Name	Execution Date														
Quintiles Transnational Corp.	03/12/2010														
Targeted Molecular Diagnostics, LLC	03/12/2010														
RECEIVING PARTY DATA															
Name:	Citibank North America, Inc. as Collateral Agent														
Street Address:	390 Greenwich Street														
City:	New York														
State/Country:	NEW YORK														
Postal Code:	10013														
PROPERTY NUMBERS Total: 6															
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:30%;">Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>11354062</td> </tr> <tr> <td>Application Number:</td> <td>12529115</td> </tr> <tr> <td>Application Number:</td> <td>61182914</td> </tr> <tr> <td>Application Number:</td> <td>61183125</td> </tr> <tr> <td>Application Number:</td> <td>61240785</td> </tr> <tr> <td>Application Number:</td> <td>61240782</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	11354062	Application Number:	12529115	Application Number:	61182914	Application Number:	61183125	Application Number:	61240785	Application Number:	61240782
Property Type	Number														
Application Number:	11354062														
Application Number:	12529115														
Application Number:	61182914														
Application Number:	61183125														
Application Number:	61240785														
Application Number:	61240782														
CORRESPONDENCE DATA															
Fax Number:	(202)408-3141														
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>															
Phone:	202-408-3121 x2348														
Email:	jpatero@cscinfo.com														
Correspondent Name:	Corporation Service Company														
Address Line 1:	1090 Vermont Avenue NW, Suite 430														
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005														
ATTORNEY DOCKET NUMBER:	33122-005														

CH \$240.00 11354062

501132382

PATENT
REEL: 024149 FRAME: 0577

NAME OF SUBMITTER:

Jean Paterson

Total Attachments: 8

source=3-29-10 Quintiles 1-PT#page1.tif

source=3-29-10 Quintiles 1-PT#page2.tif

source=3-29-10 Quintiles 1-PT#page3.tif

source=3-29-10 Quintiles 1-PT#page4.tif

source=3-29-10 Quintiles 1-PT#page5.tif

source=3-29-10 Quintiles 1-PT#page6.tif

source=3-29-10 Quintiles 1-PT#page7.tif

source=3-29-10 Quintiles 1-PT#page8.tif

FIRST LIEN PATENT SECURITY AGREEMENT

FIRST LIEN PATENT SECURITY AGREEMENT, dated as of the 12th day of March, 2010, by Quintiles Transnational Corp., a North Carolina corporation (the "Borrower"), and Targeted Molecular Diagnostics, LLC, an Illinois limited liability company ("TMD" and, together with the Borrower, the "Grantors") in favor of Citicorp North America, Inc., in its capacity as collateral agent pursuant to the Credit Agreement (as defined in the Security Agreement, defined below), as pledgee, assignee and secured party (in such capacities and together with any successors in such capacities, the "Collateral Agent").

WHEREAS, each of the Grantors has, pursuant to that certain first lien security agreement dated as of March 31, 2006 (as supplemented from time to time, the "Security Agreement"; capitalized terms used but not defined herein having the meaning assigned to such term in the Security Agreement), granted to the Collateral Agent for the benefit of the Secured Parties a security interest in and to all of the right, title and interest of such Grantor, in, to and under the Collateral, including with respect thereto, the Patents, as collateral security for the payment and performance in full when due of the Secured Obligations; and


WHEREAS, each of the Grantors and the Collateral Agent wish to further memorialize the security interest described above as it relates to the Patents identified in Schedule A, attached hereto, and incorporated herein by this reference, including but not limited to all products and proceeds thereof;

NOW THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, each of the Grantors hereby grants unto the Collateral Agent a security interest in and lien on all of its right, title and interest in the Patents identified in Schedule A, as collateral security for the payment and performance in full when due of the Secured Obligations.

[Signature page follows]


IN WITNESS WHEREOF, each of the Grantors has executed this First Lien Patent Security Agreement as an instrument as of the date first written above.

QUINTILES TRANSNATIONAL CORP.

By: 
Name: Beverly Rubin
Title: Vice President

TARGETED MOLECULAR DIAGNOSTICS,
LLC

By: QUINTILES LABORATORIES LIMITED,
as sole Member and Manager

By: 
Name: Beverly Rubin
Title: Vice President

[Signatures continue on next page]

First Lien Patent Security Agreement

PATENT
REEL: 024149 FRAME: 0580

ACKNOWLEDGMENT OF GRANTOR

STATE OF North Carolina)
COUNTY OF Durham)

ss.

On this 12th day of March, 2010, before me personally appeared Beverly Rubin, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of QUINTILES TRANSNATIONAL CORP., who being by me duly sworn did depose and say that he/she is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he/she acknowledged said instrument to be the free act and deed of said corporation.

SAIJI Y. ELDER
NOTARY PUBLIC
DURHAM COUNTY, N.C.

{seal}

Saiji Y. Elder
Notary Public

My Commission Expires: 2-7-2015

[Signatures continue on next page]


First Lien Patent Security Agreement

ACKNOWLEDGMENT OF GRANTOR

STATE OF North Carolina)
COUNTY OF Durham)

ss.

On this 12th day of March, 2010 before me personally appeared Beverly Rubin, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of TARGETED MOLECULAR DIAGNOSTICS, LLC, who being by me duly sworn did depose and say that he/she is an authorized officer of Quintiles Laboratories Limited, the sole member and manager of said company, that the said instrument was signed on behalf of said company as authorized by its sole member and manager and that he/she acknowledged said instrument to be the free act and deed of said company.



{seal}

Saiji Y. Elder
Notary Public
My Commission Expires: 2-7-2015

[Signatures continue on next page]

First Lien Patent Security Agreement

Acknowledged and Agreed:

CITICORP NORTH AMERICA, INC.

By: Susan Amrhein

Name: Susan Amrhein

Title: Vice President

First Lien Patent Security Agreement

PATENT
REEL: 024149 FRAME: 0583

SCHEDULE A

to

FIRST LIEN PATENT SECURITY AGREEMENT

Applications:

OWNER	APPLICATION NUMBER	APPLICATION DATE	COUNTRY	DESCRIPTION
Quintiles Transnational Corp.	11/354,062	2/14/2006	US	System and Method for Managing Medical Data
Targeted Molecular Diagnostics, LLC	12/529,115	3/9/2010	US	Methods and Compositions for Determining the Efficacy of Breast Cancer Therapeutics
Targeted Molecular Diagnostics, LLC	61/182,914	6/01/2009	US	Methods for the Detection and Quantitation of PTEN
Targeted Molecular Diagnostics, LLC	61/183,125	6/02/2009	US	Methods for the Detection and Quantitation of the p95 Component of Her2/Neu (ERBB2)
Targeted Molecular Diagnostics, LLC	61/240,785	9/09/2009	US	Methods and Compositions for the Treatment of Receptor Tyrosine Kinase Mediated Diseases or Disorders
Targeted Molecular Diagnostics, LLC	61/240,782	9/09/2009	US	Methods for Predicting Responsiveness of a Disease or Disorder to a Receptor Tyrosine Kinase Inhibitor by Analysis of Mutations in PIK3CA